Intracranial infection by Vibrio alginolyticus following injury in salt water.

PubWeight™: 0.94‹?›

🔗 View Article (PMC 268645)

Published in J Clin Microbiol on February 01, 1986

Authors

S M Opal, J R Saxon

Articles by these authors

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 5.86

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA (1994) 5.24

Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol (1994) 3.61

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med (1993) 2.84

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 2.66

Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med (1997) 2.14

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost (2006) 2.08

Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrob Agents Chemother (1992) 2.07

Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med (1995) 1.80

Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med (2000) 1.70

Superinfection with rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis in three patients with AIDS: confirmation by polymerase chain reaction fingerprinting. Ann Intern Med (1994) 1.54

Choice of bacteria in animal models of sepsis. Infect Immun (1993) 1.51

Spread of methicillin-resistant Staphylococcus aureus in a hospital after exposure to a health care worker with chronic sinusitis. Clin Infect Dis (1993) 1.44

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med (1994) 1.44

Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int (2001) 1.26

Malaria in travelers in Rhode Island: a review of 26 cases. Am J Med (1991) 1.23

Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit Care Med (1994) 1.23

Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med (1991) 1.16

Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis (1998) 1.16

The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. JAMA (1993) 1.14

Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol (1997) 1.09

A common-source outbreak of Staphylococcus epidermidis infections among patients undergoing cardiac surgery. J Infect Dis (1990) 1.08

Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis (1986) 1.06

Differential antibiotic-induced endotoxin release in severe melioidosis. J Infect Dis (2000) 1.05

Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res (1992) 1.04

Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis (2001) 1.04

Relapse of Pneumocystis carinii pneumonia in the upper lobes during aerosol pentamidine prophylaxis. Thorax (1989) 1.03

The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis (1993) 1.01

Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis. Clin Infect Dis (1995) 1.00

What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium. Clin Infect Dis (2000) 0.96

Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis. J Infect Dis (2000) 0.95

Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock (1994) 0.95

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock. J Exp Med (1994) 0.93

Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis (1989) 0.93

Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) (1986) 0.92

Antibiotic-induced D-lactic acidosis. Ann Intern Med (1995) 0.92

Nocardia asteroides sepsis of the knee. Clin Orthop Relat Res (1985) 0.89

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. J Infect Dis (1994) 0.88

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J Infect Dis (1996) 0.86

Plasmid, serotypic, and enterotoxin analysis of Bacillus cereus in an outbreak setting. J Clin Microbiol (1988) 0.86

Polymicrobial bacteremic pneumonia: report of three cases caused by Staphylococcus aureus and Streptococcus pneumoniae. Am Rev Respir Dis (1987) 0.85

Incidence of fever and bacteremia following transbronchial needle aspiration. Chest (1986) 0.85

Aspergillus clavatus endocarditis involving a normal aortic valve following coronary artery surgery. Rev Infect Dis (1986) 0.81

Immunotherapy of sepsis: flawed concept or faulty implementation? Vaccine (1999) 0.81

Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Scand J Infect Dis Suppl (1996) 0.81

Cytophagic histiocytic panniculitis. Systemic histiocytosis presenting as chronic, nonhealing, ulcerative skin lesions. Arch Dermatol (1985) 0.81

Testicular sarcoidosis. Am J Med (1979) 0.80

Spontaneous bacterial peritonitis: Analysis of treatment and outcome. Can J Infect Dis (1991) 0.79

Investigation of a staphylococcal food poisoning outbreak in a centralized school lunch program. Public Health Rep (1994) 0.78

Osteoporosis unmasked by hyperthyroidism in a young man with osteogenesis imperfecta. Arch Intern Med (1987) 0.78

Hemofiltration-absorption systems for the treatment of experimental sepsis: is it possible to remove the "evil humors" responsible for septic shock? Crit Care Med (2000) 0.78

Pyomyositis in a patient with the acquired immunodeficiency syndrome. Arch Intern Med (1989) 0.78

Developing a competency-based preventive medicine curriculum for medical schools. Am J Prev Med (1995) 0.78

Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis (1993) 0.77

RISE-resistant tuberculous meningitis in AIDS patient. Lancet (1993) 0.76

Protein C levels in severe sepsis. Chest (2001) 0.76

Tumor necrosis factor receptor expression on inflammatory cells in sepsis. Crit Care Med (1999) 0.75

Group B streptococcal sepsis. JAMA (1992) 0.75

An additional case of pulmonary Pseudallescheria boydii improved with ketoconazole therapy. Chest (1985) 0.75

Analysis of an outbreak of penicillinase-producing Neisseria gonorrhoeae in Rhode Island, 1987. J Clin Microbiol (1989) 0.75

The uncertain value of the definition for SIRS. Systemic inflammatory response syndrome. Chest (1998) 0.75

Selenium replacement in severe systemic inflammatory response syndrome. Crit Care Med (1999) 0.75

Travel to developing countries: pre-departure medical advice. R I Med J (1990) 0.75

Adsorption of Clostridium difficile antiserum for rapid detection of toxin. Diagn Microbiol Infect Dis (1984) 0.75

Unusual nosocomial pathogens. Infect Dis Clin North Am (1989) 0.75

Therapeutic approaches for AIDS and HIV infection. R I Med J (1987) 0.75

Rocky Mountain spotted fever in Rhode Island: case report and review of its occurrence during the past ten years. R I Med J (1988) 0.75

Malaria: the deadly threat from overseas. R I Med J (1990) 0.75

Recent advances in infectious diseases. R I Med J (1990) 0.75

Fatal clostridial sepsis in a previously healthy woman. Clin Infect Dis (1995) 0.75

The impact of converting to a biphasic blood-culture system on the overall cost and the incidence of pseudobacteremia. Diagn Microbiol Infect Dis (1992) 0.75

Pansinusitis caused by the fungus Drechslera. Otolaryngol Head Neck Surg (1985) 0.75

Antibacterial therapy in patients with malignancies. Cancer Metastasis Rev (1987) 0.75